MEI Pharma to Consider Strategic Alternatives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices ease as US-Iran truce hopes counter Saudi supply risk
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Brookline Capital Markets Downgrades MEI Pharma (MEIP) to Hold
July 22, 2024 11:52 AM EDTBrookline Capital Markets analyst Leah Rush Cann downgraded MEI Pharma (NASDAQ: MEIP) from Buy to Hold.
The analyst comments "We cover MEI Pharma, a development-stage biotechnology company working in the PI3K pathway, CDK inhibition, epigenetics, and cancer metabolism, and... More
